Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Alimera Sciences' tunnel vision is a real asset. The biopharmaceutical company specializes in prescription ophthalmic pharmaceuticals, particularly those aimed at treating ocular diseases affecting the retina. Alimera's most advanced product candidate, Iluvien, is an insert about the size of a grain of rice that slowly releases a drug to the back of the eye used in the treatment of diabetic macular edema (DME); DME, a retinal disease affecting diabetics, can lead to severe vision loss and blindness. Iluvien is effective for up to 36 months and may also have the potential to affect other ophthalmic diseases, such as retinal vein occlusion (RVO). Alimera Sciences is looking to go public through an $80 million IPO.

MaxCyte will put your blood cells to work. Its cell loading technology uses blood cells instead of viral vectors to transport gene therapies to target sites, increasing their safety and efficacy. The company partners with drug makers to help them develop more effective therapies in a shorter amount of time. Partners include AlphaVax, Sangamo BioSciences, and United Therapeutics. MaxCyte is also working on its own therapies, including potential treatments for chronic lymphocytic leukemia, lymphoma, and breast and ovarian cancer. CEO Douglas Doerfler and other backers control the company after EntreMed spun it off.

Surface Logix creates new drugs by tweaking the pharmacokinetic and pharmacodynamic properties of existing drugs and new compounds. Its Pharmacomer Technology improves a drug's solubility and permeability in the body and reduce side effects. It has a pipeline of pre-clinical and clinical candidates in development for treatment of metabolic diseases and hypertension. Its drug candidate SLx-4090 is in clinical trials to test its ability to lower blood lipid levels, reduce triglyceride uptake, and block absorption of other fats. Its SLx-2101 candidate is being investigated for treatment of hypertension and Raynaud's Syndrome.

Charles River Laboratories International, Inc. company was founded in 1947 and is headquartered in Wilmington, Massachusetts. Charles River Laboratories International, Inc. provides research models and laboratory animal support expertise to help its global partners advance their research and drug development efforts. The company offers a portfolio of services to support discovery and imaging, preclinical and early-phase clinical studies, and biopharmaceutical and endotoxin products and services for manufacturing and quality control. Its portfolio spans the entire research and drug development process, from IND consultation to discovery through market approval, allowing customized approaches to support both single-study or broad-based programs. Charles River Laboratories International serves pharmaceutical and biotechnology companies, as well as government agencies, hospitals, and academic institutions.

RegeneRx Biopharmaceuticals was founded in 1982 and is headquartered in Rockville, Maryland. RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of novel molecules to promote tissue and organ repair. The company develops its product candidates based on Thymosin beta 4 (Tb4), a 43 amino acid peptide. Its product candidates in clinical development include RGN-137, a topically applied gel for chronic dermal wounds; RGN-259, a sterile topical eye drop for ophthalmic wounds; and RGN-352, a parenteral formulation for the treatment of patients with an acute myocardial infarction, or heart attack. Its pre-clinical development product includes RGN-457, an inhaled formulation of Tb4 targeting cystic fibrosis and other pulmonary diseases. The company has a strategic partnership with Defiante Farmaceutica L.d.a. for the development and marketing of RGN-137, and certain indications relating to RGN-352 primarily in Europe.

Novartis Pharmaceuticals holds down the fort on this side of the big pond. As the US pharmaceuticals marketing affiliate of Swiss drug giant Novartis AG, the company helps with the development and sales of its parent company's products in the US. Its product line addresses a range of ailments including cardiovascular and respiratory diseases, gastrointestinal complaints, central nervous system disorders, cancer and blood disorders, bone and joint conditions, and organ transplants. Key products include tumor growth inhibitor Gleevec, high blood pressure drug Diovan, and attention deficit disorder therapies Focalin and Ritalin.

Essential Nutrition Ltd. was founded in 1989. Essential Nutrition offers research, testing, and manufacturing services to drug companies. The UK-based firm estimates its manufacturing capacity to be up to 8.5 million tablets per day. The company also produces its own brand of health food supplements which it markets online. It partners with various agronomy firms to determine optimum location and growth cycles for its herbal medicine crops, and it has developed nutritional research with universities throughout the UK and US. Essential Nutrition is family owned and operated.

Hikma Pharmaceuticals was founded in 1978 by chairman Samih Darwazah. Hikma Pharmaceuticals Plc is a speciality pharmaceutical company with operations in Europe and the United States and a focus in the Middle East and North Africa (MENA) region. The Company develops, manufactures and markets branded and unbranded generic, as well as in-licensed products in both oral and injectable dosage forms. Its operations are conducted through three segments: Branded Pharmaceuticals, Generic Pharmaceuticals and Injectable Pharmaceuticals. Hikma Pharmaceuticals Plc’s Branded Pharmaceuticals segment develops, manufactures and markets 241 solid, semi-solid and liquid branded pharmaceutical products in 460 dosage strengths and forms, including 33 products under-license from the originator. Injectable Pharmaceuticals segment develops, manufactures and markets 81 injectable products in 202 dosage strengths. Generic Pharmaceuticals develops, manufactures and markets 47 non-branded generic pharmaceutical products in 105 dosage strengths and forms.

Ikonisys is developing diagnostic tests for oncology and prenatal applications. Its lead product, fastFISH is a series of kits that help in identifying various prenatal conditions. FastFISH amnio is approved for identifying the chromosomal characteristics of birth defects such as Down syndrome, Edward's syndrome, and Patau syndrome. The company's oncoFish product line includes an FDA approved test for bladder cancer. The company is also developing a product can find chromosomal abnormalities in a fetus by testing the mother's blood, reducing the dangers associated with the standard, but invasive, amniocentesis procedure.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.